<DOC>
	<DOCNO>NCT00234884</DOCNO>
	<brief_summary>The purpose observational study observe assess long term use , safety , effectiveness adalimumab normal clinical setting .</brief_summary>
	<brief_title>Post-marketing Observational Study Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description>This multicenter , uncontrolled , 5-year observational study adalimumab treatment patient rheumatoid arthritis ( RA ) receive adalimumab least 3 month NCT00448383 ( Study M02-497 ) , interventional study end adalimumab become commercially available treatment RA . Participants receive ongoing adalimumab treatment time NCT00448383 ( Study M02-497 ) end prescribe commercial adalimumab , could receive commercial adalimumab 1 year afterward prior enrollment NCT00234884 ( Study M03-634 ) . Physician investigator encourage treat participant would patient RA routine clinical practice , free determine appropriate therapy patient . Concomitant treatment disease-modifying antirheumatic drug ( DMARDs ) , include methotrexate , could continue receive adalimumab . If treatment adalimumab permanently discontinue reason , participant discontinue study reason record . Investigators ask record adverse event 3 month last administration adalimumab .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Participants ongoing adalimumab treatment complete least Month 3 ( Visit 5 ) NCT00448383 ( Study M02497 ) subsequently prescribe adalimumab accord Summary Product Characteristics ( SmPC ) . Participants must willing consent data collect provided Abbott . Â· Participants contraindication accord SmPC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>adalimumab</keyword>
</DOC>